Table 2. Unadjusted and adjusted pooled survival estimates.
| Overall Survival (OS) | ||||||||
|---|---|---|---|---|---|---|---|---|
| Biomarker | Unadjusted HR (95% CI) | Number of Articles | n | Heterogeneity | Adjusted HR (95% CI) | Number of Articles | n | Heterogeneity |
| CD3 | 0.99 (0.87, 1.12) | 7 | 1,108 | I2 = 0.00% | 0.71 (0.37, 1.37) | 3 | 428 | I2 = 0.00% |
| Q = 1.64 (p = 0.90) | Q = 1.76 (p = 0.42) | |||||||
| CD4 | 0.76 (0.44, 1.32) | 5 | 1,037 | I2 = 34.65% | 1.00 (0.55, 1.81) | 6 | 699 | I2 = 33.79% |
| Q = 3.47 (p = 0.19) | Q = 7.55 (p = 0.18) | |||||||
| CD8 | 0.99 (0.95, 1.04) | 15 | 3,317 | I2 = 0.00% | 0.68 (0.50, 0.93) | 13 | 2,456 | I2 = 23.78% |
| Q = 10.96 (p = 0.69) | Q = 15.74 (p = 0.20) | |||||||
| CD20 | 0.45 (0.22, 0.93) | 5 | 861 | I2 = 52.29% | 0.16 (0.04, 0.64) | 1 | 113 | – |
| Q = 8.38 (p = 0.08) | ||||||||
| FoxP3 | 1.78 (1.20, 2.64) | 9 | 1,547 | I2 = 14.93% | 2.22 (1.47, 3.34) | 7 | 934 | I2 = 0.00% |
| Q = 9.40 (p = 0.31) | Q = 4.74 (p = 0.58) | |||||||
| CD56/CD57 | 0.66 (0.35, 1.25) | 3 | 258 | I2 = 13.63% | 0.50 (0.26, 0.95) | 4 | 443 | I2 = 0.00% |
| Q = 2.32 (p = 0.31) | Q = 0.22 (p = 0.97) | |||||||
| CD68 | 1.36 (0.75, 2.45) | 6# | 922 | I2 = 40.21% | 1. 13 (0.77, 1.65) | 7 | 716 | I2 = 0.00% |
| Q = 10.03 (p = 0.12) | Q = 4.18 (p = 0.65) | |||||||
| MCs | 1.81 (1.01, 3.15) | 3^ | 462 | I2 = 0.00% | 2.01 (0.88–3.92) | 3 | 604 | I2 = 43.99% |
| Q = 0.09 (p = 0.90) | Q = 5.36 (p = 0.15) | |||||||
| Disease Free Survival (DFS) | ||||||||
|---|---|---|---|---|---|---|---|---|
| Biomarker | Unadjusted HR (95% CI) | Number of Articles | n | Heterogeneity | Adjusted HR (95% CI) | Number of Articles | n | Heterogeneity |
| CD3 | 0.98 (0.86, 1.12) | 5 | 415 | I2 = 0.00% | – | – | – | – |
| Q = 2.63 (p = 0.62) | ||||||||
| CD4 | 0.72 (0.39, 1.32) | 3 | 466 | I2 = 0.00% | 0.59 (0.11, 3.12) | 1 | 105 | – |
| Q = 0.60 (p = 0.74) | ||||||||
| CD8 | 0.94 (0.77, 1.16) | 8 | 1,630 | I2 = 16.65% | 0.60 (0.41, 0.87) | 9 | 2,596 | I2 = 20.43% |
| Q = 8.39 (p = 0.30) | Q = 10.05 (p = 0.26) | |||||||
| CD20 | 0.57 (0.33, 1.00) | 4 | 540 | I2 = 0.00% | 0.51 (0.20, 1.32) | 1 | 218 | – |
| Q = 0.27 (p = 0.97) | ||||||||
| FoxP3 | 1.45 (0.81, 2.59) | 3 | 508 | I2 = 0.00% | 2.07 (1.10, 3.90) | 3 | 683 | I2 = 0.00% |
| Q = 0.07 (p = 0.96) | Q = 0.02 (p = 0.99) | |||||||
| CD56/CD57 | 1.35 (0.39, 4.66) | 1 | 84 | – | 0.59 (0.27, 1.28) | 2 | 280 | I2 = 0.00% |
| Q = 0.34 (p = 0.56) | ||||||||
| CD68 | 1.81 (0.66, 4.92 | 1 | 137 | – | 1.84 (1.02, 3.34) | 6# | 861 | I2 = 29.96% |
| Q = 7.14 (p = 0.21) | ||||||||
| MCs | 2.30 (1.20–4.70) | 1 | 201 | – | 1.50 (0.60, 3.60) | 1 | 201 | – |
#6 unique articles but 7 estimates. For Parra, 2016 adenocarcinoma and squamous histologies were evaluated separately. ^3 unique articles but 4 estimates.
HR >1 refers to high level of immune cell subtype associated with worse survival.